MARKET

RNA

RNA

Avidity Biosciences, Inc.
NASDAQ
71.83
+0.23
+0.32%
After Hours: 71.83 0 0.00% 17:56 12/12 EST
OPEN
71.59
PREV CLOSE
71.60
HIGH
71.88
LOW
71.52
VOLUME
1.98M
TURNOVER
--
52 WEEK HIGH
71.88
52 WEEK LOW
21.51
MARKET CAP
10.82B
P/E (TTM)
-17.2275
1D
5D
1M
3M
1Y
5Y
1D
XBI, EXAS, RVMD, RNA: ETF Outflow Alert
NASDAQ · 3d ago
Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity
Seeking Alpha · 4d ago
Weekly Report: what happened at RNA last week (1201-1205)?
Weekly Report · 6d ago
3 Potential Mid-Cap Biotech Buyout Targets In 2026
Seeking Alpha · 12/03 23:22
Weekly Report: what happened at RNA last week (1124-1128)?
Weekly Report · 12/01 09:49
FDA Greenlights Novartis' Gene Replacement Treatment for SMA
NASDAQ · 11/25 19:00
Sarepta's Stock Rises on Positive Updates on DM1 Therapy
NASDAQ · 11/25 18:08
BUZZ-Sarepta rises after U.S. FDA clears study of muscle-wasting disease drug
Reuters · 11/25 14:33
More
About RNA
Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. The Del-desiran is designed to treat people with myotonic dystrophy type 1 (DM1) and is in the global Phase III HARBOR trial and in the ongoing MARINA-OLE trial in people with DM1. The Delpacibart braxlosiran is the first investigational therapy designed to directly target DUX4 in people living with facioscapulohumeral muscular dystrophy (FSHD). The Del-zota is designed for people with Duchenne muscular dystrophy (DMD) and is in development with the Phase II EXPLORE44 open-label extension (OLE) study.

Webull offers Avidity Biosciences Inc stock information, including NASDAQ: RNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RNA stock methods without spending real money on the virtual paper trading platform.